|Cancer Stem Cell News 9.20 May 27, 2020|
Scientists found that long noncoding RNA (LncRNA) SOX2OT was increased in temozolomide-resistant cells and recurrent glioblastoma patient samples, and abnormal expression was correlated with high risk of relapse and poor prognosis. [Cell Death Dis]
In breast cancer cell lines, epithelial membrane protein-2 (EMP2) overexpression increased and EMP2 knockdown decreased the proportion of stem-like cells as assessed by the expression of the CSC markers CD44+/CD24–, aldehyde dehydrogenase activity, or by tumor sphere formation. [Mol Cancer Ther]
Investigators used a human CRISPR/Cas9-mixed-lineage leukemia (MLL)-rearranged leukemia model, faithfully mimicking MLLr patients’ pathology with indefinite growth potential in vitro, to evaluate the unknown role of methionine adenosyltransferase 2A (MAT2A). [Cancers]
Using in vitro and a preclinical in vivo xenograft mouse model, the authors showed that lenvatinib alone diminished CD44High/CD133High CSCs in hepatocellular carcinoma. [Carcinogenesis]
ERK2 knockdown significantly inhibited anchorage-independent colony formation and mammosphere formation, indicating compromised self-renewal capacity. [Sci Rep]
Bone marrow-derived mesenchymal stromal/stem cells (MSCs) are reportedly involved in tumorigenesis initiated by glioma stem-like cells (GSCs). Scientists therefore established three different orthotopic models of GSC-MSC interactions in vivo using dual-color fluorescence tracing. [Aging (Albany NY)]
Entrapped salinomycin maintained its cytotoxic effect on CSCs and MG63 cells, with a potency comparable to the free drug and no evident benefit was detected for folate-decorated poly(lactic acid) nanoparticles (PLA NPs) with respect to native PLA NPs. [Anal Bioanal Chem]
Researchers compared the proteomes of CD133 CSCs and CD133− differentiated glioblastoma cells stimulated by TGF-β, as well as the expression levels of the main proteins responsible for activating the signaling pathway of receptor interactions with the extracellular matrix. [Int Rev Neurobiol]
Investigators found that corrected epigenetically regulated-mRNA expression-based stemness index was significantly up-regulated in glioma samples and increased with glioma grade, with G4 having the highest stemness index. [J Mol Neurosci]
The authors summarize the current research on the small-molecule compounds suppressing CSC progression, including inhibitors of Wnt, Notch, Hedgehog, and autophagy pathways, and activators of Hippo and ferroptosis pathways. [J Hematol Oncol]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
MacroGenics, Inc. announced plans for a clinical study intended to support registration in the US of flotetuzumab, an investigational, bispecific CD123 x CD3 DART® molecule for patients with acute myeloid leukemia who are refractory to induction therapy. [MacroGenics, Inc.]
Cellectar Biosciences, Inc. announced the FDA has granted Fast Track Designation for CLR 131 in lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia in patients having received two prior treatment regimens or more. [Cellectar Biosciences, Inc.]
The National Science Foundation (NSF) would get a sweeping remake-including a new name, a huge infusion of cash, and responsibility for maintaining US global leadership in innovation-under bipartisan bills that have been introduced in both houses of Congress. [ScienceInsider]
Unfortunately for PubMed’s caretakers, a sweeping redesign unveiled this week has left many PubMed users fuming-and airing their sometimes curse-laden complaints on social media. [ScienceInsider]
In light of COVID-19, many conferences are being cancelled or postponed. As such:
We are suspending new event postings in our newsletters and on Twitter.
Visit our events page to see a complete list of events in the community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.